Caxton Associates LP grew its stake in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 115.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 35,561 shares of the biotechnology company’s stock after acquiring an additional 19,076 shares during the quarter. Caxton Associates LP’s holdings in Innoviva were worth $542,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of INVA. Bessemer Group Inc. increased its stake in shares of Innoviva by 333.5% in the 1st quarter. Bessemer Group Inc. now owns 2,211 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 1,701 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Innoviva by 124.0% during the 1st quarter. GAMMA Investing LLC now owns 2,262 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 1,252 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Innoviva by 342.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,410 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 5,736 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Innoviva during the 1st quarter worth about $138,000. Finally, Quadrant Capital Group LLC increased its position in shares of Innoviva by 13.2% during the 4th quarter. Quadrant Capital Group LLC now owns 9,042 shares of the biotechnology company’s stock worth $145,000 after purchasing an additional 1,056 shares during the last quarter. 99.12% of the stock is owned by institutional investors and hedge funds.
Innoviva Stock Performance
Shares of INVA opened at $18.99 on Wednesday. The stock has a 50-day simple moving average of $16.52 and a 200-day simple moving average of $15.81. The company has a debt-to-equity ratio of 0.63, a quick ratio of 9.17 and a current ratio of 10.42. The stock has a market capitalization of $1.19 billion, a PE ratio of 8.55 and a beta of 0.57. Innoviva, Inc. has a 1 year low of $12.22 and a 1 year high of $19.08.
Analyst Upgrades and Downgrades
INVA has been the subject of a number of recent analyst reports. StockNews.com downgraded Innoviva from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Innoviva in a report on Tuesday.
Check Out Our Latest Research Report on INVA
Innoviva Company Profile
Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Further Reading
- Five stocks we like better than Innoviva
- 5 Top Rated Dividend Stocks to Consider
- Invest Like Congress: 2 ETFs to Add to Your Watchlist
- Using the MarketBeat Stock Split Calculator
- AI Boom or Bubble? Strategies for Success in a Volatile Sector
- What Are Dividend Achievers? An Introduction
- Oilfield Infrastructure Stock Soars Over 50% on Bold Acquisition
Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva, Inc. (NASDAQ:INVA – Free Report).
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.